Adverum Biotechnologies Inc expected to post a loss of $1.31 a share - Earnings Preview

Adverum Biotechnologies

06/11/2024 13:49

* Adverum Biotechnologies Inc  ADVM.OQ   ADVM.O  is expected
to show a rise in quarterly revenue when it reports  results 
for the period ending December 31 2024
    * The Redwood City California-based  company is expected to
report
revenue of $87.5 thousand, according to the mean estimate from 6
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Adverum Biotechnologies
Inc is
for a loss of $1.31 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 8.8%
in the last three months. ​
    * Wall Street's median 12-month price target for Adverum
Biotechnologies Inc is $30.00​, above​ its last closing price
of $7.72. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -1.29       -1.31      -1.30     Beat    0.5
 Jun. 30 0001  -1.44       -1.47      -0.89     Beat    39.4
 Mar. 31 2024  -1.55       -1.40      -1.50     Missed  -6.8​
 Dec. 31 2023  -3.35       -3.37      -2.30     Beat    31.7
 ​​Sep.        -3.06       -3.15      -3.30     Missed  -4.7
 30 2023                                                
 Jun. 30 2023  -3.12       -3.29      -3.10     Beat    5.7​
 Mar. 31 2023  -3.20       -3.20      -2.90     Beat    9.5
 Dec. 31 2022  -3.72       -3.62      -3.30     Beat    8.9
 This summary was machine generated November 6 at 13:49 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)